BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/10/2021 9:08:48 AM | Browse: 551 | Download: 939
 |
Received |
|
2021-02-18 11:44 |
|
Peer-Review Started |
|
2021-02-18 11:51 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-13 00:45 |
|
Revised |
|
2021-06-09 09:32 |
|
Second Decision |
|
2021-11-29 03:35 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-11-29 19:42 |
|
Articles in Press |
|
2021-11-29 19:42 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-12-07 02:45 |
|
Publish the Manuscript Online |
|
2021-12-10 09:08 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Minireviews |
| Article Title |
COVID-19 and gut immunomodulation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Koushik Roy, Sidra Agarwal, Rajib Banerjee, Manash K Paul and Prabhat K Purbey |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Manash K Paul, PhD, Research Scientist, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles, 700 Tiverton Ave (at Charles E. Young Dr. E.), Los Angeles, CA 90095, United States. manashp@ucla.edu |
| Key Words |
COVID-19; Gastrointestinal symptoms; Pathogenesis; Innate immune response; Adaptive immune response; Gut microbiota; Dysbiosis; Therapeutics; Probiotic; Pre-existing diseases |
| Core Tip |
COVID-19 is a global pandemic. Many COVID-19 patients either present gastrointestinal (GI) symptoms in addition to respiratory symptoms or just GI symptoms. SARS-CoV-2 directly infects GI epithelial cells as they express significant levels of angiotensin-converting enzyme-2 and transmembrane protease serine 2 protein, required for SARS-CoV-2 entry. This article reviews gut infection and GI immunomodulation by SARS-CoV-2, leading to spectrum of GI symptoms and pathogenesis in COVID-19-patients. Special emphases are given on the innate and acquired immune responses in the GI tract due to intestinal and non-intestinal SARS-CoV-2 infection, COVID-19 severity in people with pre-existing intestinal diseases, role of gut microbiota, and possible therapeutic interventions are discussed. |
| Publish Date |
2021-12-10 09:08 |
| Citation |
Roy K, Agarwal S, Banerjee R, Paul MK, Purbey PK. COVID-19 and gut immunomodulation. World J Gastroenterol 2021; 27(46): 7925-7942 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i46/7925.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i46.7925 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
